Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma: Editorial comment

Samir S. Taneja

    Research output: Contribution to journalComment/debate

    Original languageEnglish (US)
    Pages (from-to)2149-2150
    Number of pages2
    JournalJournal of Urology
    Volume188
    Issue number6
    DOIs
    StatePublished - Dec 2012

    ASJC Scopus subject areas

    • Urology

    Cite this